MedKoo Cat#: 406496 | Name: CH5015765

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CH5015765 is a novel, potent, and selective HSP90 inhibitor. CH5015765 showed high affinity for Hsp90 and antitumor activity in human cancer xenograft mouse models.

Chemical Structure

CH5015765
CH5015765
CAS#959766-47-3

Theoretical Analysis

MedKoo Cat#: 406496

Name: CH5015765

CAS#: 959766-47-3

Chemical Formula: C16H13ClN4OS

Exact Mass: 344.0499

Molecular Weight: 344.82

Elemental Analysis: C, 55.73; H, 3.80; Cl, 10.28; N, 16.25; O, 4.64; S, 9.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CH5015765; CH-5015765; CH 5015765
IUPAC/Chemical Name
4-(5-chloro-1,3-dihydrobenzo[de]isochromen-6-yl)-6-(methylthio)-1,3,5-triazin-2-amine.
InChi Key
FPTCGMGLTQPTGE-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H13ClN4OS/c1-23-16-20-14(19-15(18)21-16)13-10-4-2-3-8-6-22-7-9(12(8)10)5-11(13)17/h2-5H,6-7H2,1H3,(H2,18,19,20,21)
SMILES Code
NC1=NC(C2=C3C(C(COC4)=CC=C3)=C4C=C2Cl)=NC(SC)=N1
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Structure comparison between CH5015765, CH5138303, and CH5164804      

Preparing Stock Solutions

The following data is based on the product molecular weight 344.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Suda A, Kawasaki K, Komiyama S, Isshiki Y, Yoon DO, Kim SJ, Na YJ, Hasegawa K, Fukami TA, Sato S, Miura T, Ono N, Yamazaki T, Saitoh R, Shimma N, Shiratori Y, Tsukuda T. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors. Bioorg Med Chem. 2014 Jan 15;22(2):892-905. doi: 10.1016/j.bmc.2013.11.036. Epub 2013 Nov 25. PubMed PMID: 24369839. 2: Suda A, Koyano H, Hayase T, Hada K, Kawasaki K, Komiyama S, Hasegawa K, Fukami TA, Sato S, Miura T, Ono N, Yamazaki T, Saitoh R, Shimma N, Shiratori Y, Tsukuda T. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1136-41. doi: 10.1016/j.bmcl.2011.11.100. Epub 2011 Dec 1. PubMed PMID: 22192591. 3: Miura T, Fukami TA, Hasegawa K, Ono N, Suda A, Shindo H, Yoon DO, Kim SJ, Na YJ, Aoki Y, Shimma N, Tsukuda T, Shiratori Y. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5778-83. doi: 10.1016/j.bmcl.2011.08.001. Epub 2011 Aug 6. PubMed PMID: 21875802.